We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App

New Blood Test Simplifies PCOS Diagnosis

By LabMedica International staff writers
Posted on 13 Feb 2024
Print article
Image: The Elecsys AMH Plus has received a CE mark as a diagnostic blood test for PCOS (Photo courtesy of Roche)
Image: The Elecsys AMH Plus has received a CE mark as a diagnostic blood test for PCOS (Photo courtesy of Roche)

Polycystic ovarian syndrome (PCOS), a common endocrine disorder affecting about 1 in 8 women of reproductive age, leads to anovulatory subfertility. Its diagnosis typically involves a combination of blood tests, including hormone profiling, ultrasound, and patient history. However, diagnosing PCOS, which encompasses a spectrum of physical and emotional health issues, has been challenging, with an estimated 70% of cases going undiagnosed. A few studies have suggested that an anti-Müllerian hormone (AMH) level exceeding 3.8–5 ng/mL could be indicative of PCOS. Now, an immunoassay, previously used in fertility diagnostics, presents a non-invasive alternative to traditional transvaginal ultrasound for PCOS diagnosis.

The Elecsys AMH Plus immunoassay from Roche Diagnostics (Basel, Switzerland) offers a less invasive, more comfortable, and possibly quicker method for diagnosing PCOS. This approach is particularly advantageous for those who are uncomfortable with transvaginal ultrasounds or are not sexually active. AMH, produced by granulosa cells in ovarian follicles, is found in higher quantities in patients with PCOS due to an increased number of follicles producing high levels of AMH. Studies have demonstrated that elevated AMH levels are a reliable diagnostic marker for PCOS. The Elecsys AMH Plus immunoassay aligns with the revised 2023 Rotterdam Criteria, which now recognizes that high AMH levels can indicate polycystic ovarian morphology (PCOM), a key marker of PCOS.

This development in both diagnostic criteria and technology marks a significant advancement in catering to the needs of women with PCOS. It offers an alternative to invasive transvaginal ultrasounds and could enhance early diagnosis rates. Roche has secured CE-mark regulatory approval for the Elecsys AMH Plus immunoassay, marking a pivotal moment in women’s healthcare, especially in addressing the widespread underdiagnosis of PCOS. Through this innovation, Roche aims to broaden access to PCOS diagnosis and promote early interventions to manage the condition, thereby mitigating risks of long-term complications such as type 2 diabetes.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more


view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.